Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer (ICONIC Trial)
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2018
At a glance
- Drugs Avelumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ICONIC
- 05 Jun 2018 According to trial design data presented at the 54th Annual Meeting of the American Society of Clinical Oncology, an interim analysis will assess safety and Mandard tumour regression grading (TRG) after 15 patients become evaluable.If greater than or equal to 5 patients achieve TRG 1-3 the trial will expand to 40 patients.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 08 Feb 2018 Planned number of patients changed from 38 to 40.